October 2025. Reviews issues in specialty pharmacy dispensing and distribution of rare disease and gene therapy medications. Examines network considerations, specialty pharmacy capabilities, contracting approaches, and best-in-class manufacturer engagement/support.
2025 Research
September 2025. Examines commercial plans' management of high and ultra high-cost therapies, discusses financing and contracting mechanisms, and evaluates best-in-class manufacturer support and commercial MCO needs going forward.
August 2025. Reviews contract prevalence with key commercial payer segments, most common contracting approaches, and rebate/discount amounts offered across 40+ therapeutic areas spanning traditional, specialty and oncology.
-
Specialty pharmacies have developed robust and unique capabilities to support the growing market of rare disease & gene therapies, and can serve as strong partners in patient access and adherence...
-
A growing volume of innovative rare disease and gene therapy treatments continue to enter the market, requiring novel utilization management, financing, and contracting approaches. HIRC’s report,...
-
Pharmaceutical manufacturer contracting is a key element of account engagement to enhance and/or maintain market access; however, the contracting landscape can vary greatly by therapeutic area. HIRC'...
HIRC Special Report Series
Special Report Topics
Special report topics vary annually based upon the current health care environment. Research directors and consultants select topics or insights that are highly relevant, of high interest, and/or are critical for manufacturers to be aware of. Special reports often draw upon data across HIRC services, allowing readers to glean insights into high level topics across varying market segments, channels, and/or therapeutic areas.
Emerging Innovative Therapies
Part of the Specialty Report Series is HIRC's increasingly renown rare disease & gene therapy insights, covering payer management and financing approaches as well as issues in specialty pharmacy provider distribution. The following rare disease categories are examined in-depth:
- Gene Therapy
- Genetic Diseases: Duchenne Muscular Dystrophy, Hereditary Angioedema, Spinal Muscular Atrophy, Transthyretin Amyloidosis (hATTR/ATTR)
- Blood Disorders: Hemophilia, Paroxysmal Nocturnal Hemoglobinuria (PNH), Sickle Cell Disease, Thrombocytopenia/ thrombocythemia
- Cancer/Oncology: Rare Cancers, Rare Blood Cancers
- And More: Amyotrophic Lateral Sclerosis (ALS), Idiopathic Pulmonary Fibrosis, Myasthenia Gravis, Pulmonary Arterial Hypertension, Rare Cardiovascular Diseases (e.g., HCM, HoFH, Recurrent Pericarditis), Rare Liver Diseases (e.g., AHP, Alagille, PBC, PFIC), Rare Kidney Diseases (e.g., C3G, PH1, IgAN/Bergers), Rare Sleep Disorders (e.g., narcolepsy, idiopathic hypersomnia), Rare Neurological Diseases (e.g., rare epilepsies, Huntington’s, Rett, Niemann-Pick)
